In a major disappointment for Johnson & Johnson (JNJ), the US Food and Drug Administration (FDA) has asked the company to strengthen the warning for its HIV drug Intelence regarding a deadly skin reaction. The warning has been updated after the death of a patient from the skin reaction known as toxic epidermal necrolysis was reported. Additionally, another case of liver failure was reported in a patient who subsequently recovered. Since the launch of Intelence in January 2008, the product has included a warning about the risk of severe skin reactions, though the rate of serious allergic reactions was quite less in the clinical trials (less than 0.1%). The drug, used in combination therapy for HIV treatment, has marketing authorization in Canada and the European Union as well. J&J has asked the doctors to stop administering Intelence if any case of such allergic reaction is noticed....

Pharmaceuticals and dermatology go hand in hand. Existing skin care products cover a wide range of capabilities. Some are to aide with an allergic reaction. Some slow the elasticity process of aging. Some offer concealment to blemishes. Whatever the type used, this industry is huge, really huge. Even as we live in such uncertain times, the salon and skin care industries are running at peak performance. It is not just one or two areas of that market doing well either, it is abroad. Because of technology accompanied by a host of pharmaceutical scientists, researchers, and those dedicated to the skin care industry, it is constantly blooming with new activity.

Topically delivered products are becoming more popular by the day. It is these products that boast how far technology has come. These products protect the skin from environmental irritants and allows for normal skin respiration while reducing overall irritation. Concepts

...